This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Spencer Trask Congratulates InVivo Therapeutics On Its Recent Approvals From The FDA

GREENWICH, Conn., April 5, 2013 /PRNewswire/ -- Spencer Trask, a venture capital firm focused on developing big ideas into world-changing companies, congratulates InVivo Therapeutics (NVIV), for its recent approvals from the U.S. Food and Drug Administration (FDA). On the heels of FDA approval for Humanitarian Use Device (HUD) designation (an important benchmark and speed-to-market catalyst), InVivo has received yet another important FDA approval – Investigational Device Exemption (IDE), allowing human trials to begin. 

With IDE approval, InVivo will now be able to run first-in-man clinical trials to confirm safety and performance of its biopolymer scaffold. There are currently no treatment options approved by the FDA, or in clinical trials, to intervene directly in the spinal cord following a spinal cord injury. "We believe InVivo's treatment for spinal cord injuries could have a profound impact. If this is approved, it will change lives," said Kevin Kimberlin, Chairman of Spencer Trask & Co. "This is what we are all about – helping entrepreneurs brave enough to work on tough problems, like ending paralysis due to spinal cord injuries."

Spencer Trask Ventures raised $13 million in early-stage funding for InVivo in December of 2010 through its network of individual investors at a share price of $1.00

"The funding from Spencer Trask came at a critical time in InVivo's growth – it enabled us to take the next step and expand our facility," said Frank Reynolds, CEO of InVivo Therapeutics. "That was an important milestone for InVivo, and I want to thank those early investors for helping us grow our big idea. These recent FDA approvals take us two giant steps closer to achieving a viable treatment for spinal cord injuries." 

Other Spencer Trask firsts include: Myriad Genetics, the first human genome company; Ciena, the first wave division multiplexing system to power the Internet; Osiris, the first company with an FDA-approved stem cell therapy; and Next Level Communications, the first VDSL broadband system.

About Spencer Trask & Co. and Spencer Trask Ventures Spencer Trask is a venture capital firm that transforms bright ideas into great companies. Through a collaborative network of business leaders, domain experts and individual investors, Spencer Trask builds market-leading companies with a sustainable competitive advantage. Clients invest on a deal-by-deal basis rather than through a fund. Spencer Trask Ventures is a wholly owned subsidiary of Spencer Trask & Co.

SOURCE Spencer Trask

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs